Latest News

  • Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences Read More
  • Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™ Read More
  • Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting Read More

Investors

ALKS investor relations
Learn more Learn More

Pipeline

patient focused CNS disorder treatments
See Our Approach See Our Approach

Working at Alkermes

career opportunities at Alkermes
Working at Alkermes Join Our Team